Study That Will Evaluate the Brazilian Population With COPD.

Last updated: June 13, 2025
Sponsor: AstraZeneca
Overall Status: Active - Recruiting

Phase

N/A

Condition

Copd (Chronic Obstructive Pulmonary Disease)

Treatment

N/A

Clinical Study ID

NCT06780046
D5980R00117
  • Ages > 18
  • All Genders

Study Summary

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients of both sexes, aged 18 years or older, with confirmed COPD according toGOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT >=10); or

  • GOLD E (>=2 moderate or 1 severe exacerbation - hospitalization); or

  • GOLD 3 and 4 (FEV1 <50%).

Exclusion

Exclusion Criteria:

  • Advanced fibrosing interstitial lung disease (extent >=50%); and/or

  • High-risk pulmonary hypertension (on triple therapy); and/or

  • Active cancer - on systemic therapy

Study Design

Total Participants: 693
Study Start date:
January 31, 2025
Estimated Completion Date:
February 26, 2027

Study Description

This is a prospective multicentre cohort, non-interventional study. The design is to have multiple medical centres representing the regions of Brazil. Each region has a different exposure to risk factors like tobacco smoke, biomass burning and environmental pollution, has a different population composition and density, degree of urbanization and education level. There are also some inferred genetic differences due to previous colonization and miscegenation. *CAT (COPD Assessment Test) OU CAAT (Chronic Airway Assesment Test) poderão ser usados intercambiavelmente. The patients will be enrolled in non-random consecutive method and will be followed up for 12 months.

There will be on-site visits at inclusion (V0), 6 and 12 months. There will tele-consults at 3 and 9 months to gather relevant clinical data, with special interest at exacerbation.

There will be 8 participating centres in Brazil, representing all 5 regions (North, Northeast, Midwest, Southeast and South). They will be Teaching Hospitals, Regional Reference Hospitals, Tertiary Hospitals or High Complexity Hospitals. The data will be collected on each site and will be adjudicated by the ARO Team.

Connect with a study center

  • Centro de Pesquisa Clinica do Instituto Israelita de Ensino (HIAE)

    Sao Paulo,
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.